Home > Business Development > In-licensing & Co-Work   
 
Hyundai is your best choice for a partner to help your business for gaining rapid and efficient entry into the Korean market, and create a stable source of continuing profits.

Hyundai has outstanding professional teams who are considered to be most experienced in clinical trials, regulatory affairs, and marketing in Korea.

Hyundai's goal is to make significant scientific contributions and to be a recognized performance leader in local market where we provide innovative, valuable drugs to the patients

Hyundai accomplished fast market penetration of licensed products by simultaneously conducting multi-national trials with licensors.

Hyundai offers various business options to our partners such as co-marketing, co-promotion, joint-ventures and equity investment. We established the basis of these models by the needs of our business partners.

Following therapeutic areas are targets Hyundai is actively seeking and focusing on ;
  • Cardiovascular disorder such as hypertension
  • Endocrinology disorder such as Type I, II Diabetes & Diabetic complications
  • CNS disorder such as Depression, Schizophrenia, Anxiety disorder, Insomnia, Alzheimer's disease, Parkinson's disease and Various pain types
  • Ophthalmic disorder
  • Respiratory disorder
  • Oncology disorder
  • Degenerative/Age-related diseases If you have a partnering opportunity you would like to discuss with Hyundai, Please email Byung-Girl,Rhee / (BD@hdpharm.co.kr)

YEAR
EVENT
2020
Ferring Pharmaceuticals Korea
Co-Promotion Agreement for three women’s health products (Tractocile Injection, Duratocin RTS Injection, Propess Vaginal SR Tablet)

Sandoz Korea
Co-Promotion Agreement for three anti-depressant products (Escitalopram Tablet, Sertraline Tablet, Paroxetine Tablet)
2019
NEUROCHLORE (France)
Exclusive License Agreement for the Autism Spectrum Disorder treatment candidate

Seoul Saint Mary’s Hospital & KRICT (Korea)
Exclusive License Agreement for the “Composition for Hardening Soft Tissue”

BAUSCH & LOMB (USA)
Exclusive Distribution Agreement for Emerade, an adrenaline auto-injector for anaphylaxis
2018
MITHRA Pharmaceuticals (Belgium)
Exclusive License and Supply Agreement for Estelle, a novel combined oral contraceptive (COC) product candidate
2016
ACERUS Pharmaceuticals (Canada)
Exclusive License and Supply Agreement for Natesto, a testosterone nasal gel for replacement therapy in adult males
2015
ASLAN Pharmaceuticals (Singapore)
Collaboration and License Agreement for ASLAN001 (Varlitinib), a drug candidate for the treatment of advanced biliary tract cancer

Takeda Korea
Exclusive Distribution Agreement for Tachosil (Pre-rolled), a dual action surgical hemostatic patch

CHEMO (Spain)
Exclusive License and Supply Agreement for Lania (Levonorgestrel, Ethinyl Estradiol), a generic combined oral contraceptive (COC) product

Pfizer Korea
Co-Promotion Agreement for Duavive, a new menopausal hormone therapy (MHT)

Abbott Korea
Co-Promotion Agreement for Hokunalin Patch, a treatment of relief of various symptoms, such as dyspnea, resulting from airway obstruction in bronchial asthma, acute bronchitis, chronic bronchitis, and pulmonary emphysema
2014
DUCHESNAY (Canada)
Exclusive License and Supply Agreement for Diclectin indicated for the management of nausea and vomiting of pregnancy

CHEMO (Spain)
Exclusive License and Supply Agreement for Bonita (Desogestrel, Ethinyl Estradiol), a generic combined oral contraceptive (COC) product
2012
Takeda Korea
Exclusive Distribution Agreement for Tachosil, a dual action surgical hemostatic patch
2011
Bausch & Lomb South Asia Inc.
Co-Promotion Agreement for Ocuvite eye vitamin and mineral supplements with lutein

Ophtecs (Japan)
Exclusive License and Supply Agreement for Looping, a preservative free artificial tear drop
 
main_footer